Overview
Chris Shorey is an associate in the Mergers & Acquisitions practice at Paul Hastings and is based in the firm's Boston office.
Chris advises public and private companies, financial institutions and investors in a broad range of domestic and cross-border transactional matters, including mergers and acquisitions, divestitures, minority investments and other strategic transactions, as well as advising in other corporate and securities matters, including corporate governance, SEC reporting and general corporate and commercial matters.
Chris has substantial transactional involvement across numerous industries, including healthcare, media and entertainment, technology, consumer products and industrial.
Prior to joining Paul Hastings in 2025, Chris was an associate in the M&A group in the Boston office of another leading global law firm.
Education
- Duke University School of Law, J.D., 2021
- The Fuqua School of Business, M.B.A., 2021
- Colby College, B.A., 2016
Representations
- 908 Devices Inc. in its sale of its portfolio of desktop devices used in the field of bioprocessing process analytical technologies to Repligen Corporation.
- Paratek Pharmaceuticals, Inc. in its sale to Gurnet Point Capital and Novo Holdings.
- Provention Bio in its $2.9 billion sale to Sanofi.
- Signify Health in its sale to CVS Health in an all-cash transaction valued at approximately $8 billion in total consideration.
- America’s Test Kitchen in its sale to Marquee Brands.
- Pfizer Inc. in its $6.7 billion acquisition of Arena Pharmaceuticals, Inc.
Matters may have been completed before joining Paul Hastings.